Newsroom

Pure-DEL has received CHF 150,000 from Venture Kick to target the undruggable

18.11.2025

ETH spin-off Pure-DEL has received CHF 150,000 from Venture Kick to advance its technology for tackling some of the most challengi ... more

CHF 40,000 for AI property management, targeted cancer drugs, and 3D engineering tools

17.11.2025

Bewy, Biodelphis Therapeutics, and nureo were selected in the second stage of Venture Kick’s support program. Their projects inclu ... more

GlioCART receives CHF 150,000 from Venture Kick to fight the most aggressive form of brain cancer

17.11.2025

GlioCART has obtained CHF 150,000 from Venture Kick to develop a new type of cell therapy – the first CAR-T cell therapy – designe ... more

more

Media contacts

For media enquiries, please email our communications team. If you have a general question about Venture Kick please visit our about us page.

Learn more about Venture Kick or download the latest annual report for detailed information.